Systemic sclerosis & Raynaud's
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review
Authors' conclusion
Prokinetic drugs may improve GI motility and symptoms in patients with SSc.
Study context
- Population
- Patients with SSc and gastrointestinal involvement (GI) involvement (dysmotility)
- Participants
- 21 studies
- Comparison
- Prokinetic agents for SSc-related GI dysmotility
- Cisapriden = 5
- Metoclopramiden = 7
- Octreotiden = 4
- Prucalopriden = 1
- Outcome
- Effects of prokinetic agents on GI function and/or GI symptoms
Methodological detailsqualitative data synthesis, PubMed and Embase
- Qualitative data synthesis
- PubMed and Embase
Main finding
As reported in the abstract
- Metoclopramide consistently improved overall GI motility
- Cisapride improved gastric emptying and colonic motility, but not oesophageal motility
- Octreotide improved small bowel motility but delayed gastric emptying
- Prucalopride, the only one evaluated with a validated patient questionnaire, improved both upper and lower GI symptoms
- 13 studies on GI motility by objective tests, 8 on clinical responses, 6 both
Original publication
The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review. Rheumatology (Oxford). Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →